** Shares of gene therapy maker Sarepta Therapeutics SRPT.O rise 1.8% to $51.19

** Wells Fargo starts coverage on SRPT with "overweight" rating and sets PT at $115

** The new price target represents more than double the upside to stock's last close

** Brokerage says SRPT's muscle disorder therapy, Elevidys, remains best option for most young patients with Duchenne muscular dystrophy, so commercial opportunity is largely intact

** SRPT said last week it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment

** Wells Fargo sees no significant impact to the company due to the event

** Brokerage expects global sales of $1.6 billion in 2025 and peak sales of $3.5 billion in 2028 for Elevidys

** Twenty of 24 brokerages rate the stock "buy" or higher, four "hold"; their median PT is $158.09 - data compiled by LSEG

** Up to last close, shares have fallen 58.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))